Clinical Trial Update: EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for EMB-01 in combination with Osimertinib in EGFR-mutant lung cancer, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr Mutation-related Tumors
• Lung Cancer Ajcc V8
• Lung Non-small Cell Carcinoma
• Stage Iiia Lung Cancer Ajcc V8
• Stage Iiib Lung Cancer Ajcc V8
• Stage Iva Lung Cancer Ajcc V8
• Stage Ivb Lung Cancer Ajcc V8

Drugs mentioned

• EMB-01
• Osimertinib (osimertinib)

Snippet

Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN